Genmab A (GMAB) Current Deferred Revenue (2020 - 2026)
Genmab A's (GMAB) quarterly Current Deferred Revenue came in at $88.0 million in Q1 2026, up 25.71% YoY from $70.0 million in Q1 2025, and down 7.37% on a QoQ basis from $95.0 million in Q4 2025.
Genmab A (GMAB) Current Deferred Revenue (2020 - 2026) Analysis & Trends
Genmab A (GMAB) has 5 years of Current Deferred Revenue data on file, last reported at $88.0 million in Q1 2026.
- Quarterly Current Deferred Revenue rose 25.71% year-over-year to $88.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88.0 million (up 25.71% YoY) and the FY2025 annual result came in at $95.0 million, up 3066.67% from the prior year.
- Current Deferred Revenue fell to $88.0 million in Q1 2026, from $95.0 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $95.0 million in Q4 2025 to a low of $3.0 million in Q4 2024.
- A 4-year average of $56.4 million and a median of $67.0 million in 2025 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2024 — Current Deferred Revenue plunged 40.0% — and 2025, when it soared 3066.67%.
- Tracing GMAB's Current Deferred Revenue over 4 years: stood at $5.0 million in 2023, then sank by 40.0% to $3.0 million in 2024, then soared by 3066.67% to $95.0 million in 2025, then slipped by 7.37% to $88.0 million in 2026.
- The last three Current Deferred Revenue figures came in at $88.0 million (Q1 2026), $95.0 million (Q4 2025), and $67.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.00 Mn |
| Mar 31, 2026 | 88.00 Mn |
| Dec 31, 2025 | 95.00 Mn |
| Sep 30, 2025 | 67.00 Mn |
| Jun 30, 2025 | 67.00 Mn |
| Mar 31, 2025 | 70.00 Mn |
| Dec 31, 2024 | 3.00 Mn |
| Dec 31, 2023 | 5.00 Mn |
| Sep 30, 2020 | 487.00 |